• Celltrion signed a licensing agreement with US-based Kaigene on Oct. 22, 2026, for long-acting anti-APRIL antibody KG013.
• The deal is worth up to USD 580.5 million, including upfront payments and development, regulatory and sales milestones.
• KG013 targets immune diseases including IgA nephropathy, using half-life extension technology to improve durability over first-generation treatments.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celltrion Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261022800167), on October 22, 2026, and is solely responsible for the information contained therein.